Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
Stephen D Smith, Suchitra Sundaram, Sharmila Giri et al.
✦ AI-curated · Sources linked
In 30 seconds
The CARiBOU trial, a phase 2 multicenter study, evaluated a multitargeted first-line treatment for mantle cell lymphoma (MCL) in 41 previously untreated patients. The regimen, combining VR-CAP and R-cytarabine with continuous acalabrutinib, achieved a complete metabolic response (CMR) rate of 90%, with 39 patients responding to therapy. The study highlights the potential for effective outpatient management of MCL.
Key findings
- 90% of patients achieved complete metabolic response (CMR) with the treatment.
- 79% of patients had undetectable measurable residual disease (MRD) at a 10^6 threshold.
- 18-month estimated progression-free survival (PFS) was 79% and overall survival (OS) was 96%.
- 78% of patients experienced grade 3 hematologic adverse events.
Why it matters
This study demonstrates a promising outpatient treatment strategy for mantle cell lymphoma, potentially improving patient outcomes through a high CMR rate and manageable toxicity. Understanding these results can guide clinicians in treatment planning and patient management.